CR20170080A - Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace - Google Patents

Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace

Info

Publication number
CR20170080A
CR20170080A CR20170080A CR20170080A CR20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A
Authority
CR
Costa Rica
Prior art keywords
alzheimer
combination therapy
bace inhibitor
abeta antibodies
n3pglu abeta
Prior art date
Application number
CR20170080A
Other languages
English (en)
Inventor
Patrick Cornelious May
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20170080A publication Critical patent/CR20170080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Massaging Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad neurodegenerativa o cognitiva, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad eficaz de un compuesto de la fórmula: o una sal farmacéuticamente aceptable de este; en combinación con una cantidad eficaz de un anticuerpo monoclonal Abeta anti-N3pGlu.
CR20170080A 2014-09-16 2015-09-08 Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace CR20170080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16
PCT/US2015/048807 WO2016043997A1 (en) 2014-09-16 2015-09-08 Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor

Publications (1)

Publication Number Publication Date
CR20170080A true CR20170080A (es) 2017-03-30

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170080A CR20170080A (es) 2014-09-16 2015-09-08 Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace

Country Status (27)

Country Link
US (1) US9999624B2 (es)
EP (1) EP3193882A1 (es)
JP (1) JP6339741B2 (es)
KR (1) KR101871128B1 (es)
CN (1) CN106687136A (es)
AP (1) AP2017009794A0 (es)
AR (1) AR101740A1 (es)
AU (1) AU2015318257B2 (es)
BR (1) BR112017003571A2 (es)
CA (1) CA2956835A1 (es)
CL (1) CL2017000558A1 (es)
CO (1) CO2017001875A2 (es)
CR (1) CR20170080A (es)
DO (1) DOP2017000071A (es)
EA (1) EA031764B1 (es)
EC (1) ECSP17015977A (es)
IL (1) IL250387A0 (es)
MX (1) MX2017003414A (es)
NZ (1) NZ728636A (es)
PE (1) PE20170464A1 (es)
PH (1) PH12017500493A1 (es)
SG (1) SG11201701330PA (es)
SV (1) SV2017005389A (es)
TN (1) TN2017000072A1 (es)
TW (1) TWI599358B (es)
WO (1) WO2016043997A1 (es)
ZA (1) ZA201700826B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511500A (ja) * 2016-03-15 2019-04-25 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミロイドベータの蓄積に関連する障害の処置のためのｂａｃｅ阻害剤と抗体または抗原結合性断片との組合せ
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2018034977A1 (en) 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
JP2020500841A (ja) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノンの投与を含む併用療法
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
BR112019016815A2 (pt) 2017-12-14 2020-04-07 H Lundbeck As tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
WO2021216372A1 (en) * 2020-04-23 2021-10-28 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016876A2 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
UA101352C2 (uk) 2008-01-18 2013-03-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Конденсоване похідне амінодигідротіазину
PL3339323T3 (pl) * 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
EA031764B1 (ru) 2019-02-28
US9999624B2 (en) 2018-06-19
IL250387A0 (en) 2017-03-30
PH12017500493A1 (en) 2017-08-07
BR112017003571A2 (pt) 2017-12-19
AU2015318257A1 (en) 2017-02-16
CO2017001875A2 (es) 2017-05-19
ECSP17015977A (es) 2018-03-31
TWI599358B (zh) 2017-09-21
JP2017529348A (ja) 2017-10-05
AR101740A1 (es) 2017-01-11
WO2016043997A1 (en) 2016-03-24
CL2017000558A1 (es) 2017-11-10
DOP2017000071A (es) 2017-06-15
SG11201701330PA (en) 2017-04-27
TN2017000072A1 (en) 2018-07-04
JP6339741B2 (ja) 2018-06-06
CN106687136A (zh) 2017-05-17
AU2015318257B2 (en) 2018-06-14
PE20170464A1 (es) 2017-04-26
SV2017005389A (es) 2018-01-17
KR101871128B1 (ko) 2018-06-25
EP3193882A1 (en) 2017-07-26
ZA201700826B (en) 2018-12-19
CA2956835A1 (en) 2016-03-24
MX2017003414A (es) 2017-06-19
EA201790305A1 (ru) 2017-07-31
TW201618786A (zh) 2016-06-01
US20170224702A1 (en) 2017-08-10
NZ728636A (en) 2018-05-25
AP2017009794A0 (en) 2017-03-31
KR20170036103A (ko) 2017-03-31

Similar Documents

Publication Publication Date Title
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CU24498B1 (es) Anticuerpos de factor xi
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
PE20170673A1 (es) Terapia de combinacion para tratar una paramixovirus
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
NZ712207A (en) Tetrahydropyrrolothiazine compounds
DOP2017000178A (es) Inhibidores selectivos de bace1
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
EA201691541A1 (ru) Новые анти-baff антитела
BR112017002433A2 (pt) anticorpos anticeramida
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
BR112018002763A2 (pt) método para cicatrização de ferimentos
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201990559A1 (ru) Комбинированная терапия
MX2016008968A (es) Compuestos organicos.
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
EA201792282A1 (ru) Способы лечения заболеваний